A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial

References

• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Forbes K, Lussier D, et al. Difficult pain problems: an integrated approach. In: Doyle D, Hanks G, Cherny N, Calman K (eds). Oxford Textbook of Palliative Medicine, 3rd edn. Oxford: Oxford University Press, 2004: 438-58
   Google Scholar
• Skinner C, Thompson E, Davies A. Clinical features. In: Davies A (ed). Cancer-Related Breakthrough Pain. Oxford: Oxford University Press, 2006: 13-22
   Google Scholar
• Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag 2002;24:45-52
   PubMed Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9
   PubMed Web of Science ®Google Scholar
• Davies A. Introduction. In: Davies A (ed). Cancer-Related Breakthrough Pain. Oxford: Oxford University Press, 2006: 1-11
   Google Scholar
• Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 1997;5(Suppl. 16):7-12
   Google Scholar
• Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34
   PubMed Web of Science ®Google Scholar
• Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manag 2000;20:87-92
   PubMed Web of Science ®Google Scholar
• Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;3:38-44
   PubMed Web of Science ®Google Scholar
• Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain. Am J Manag Care 2008;14:S129-40
   PubMedGoogle Scholar
• Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy Jr JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30
   PubMed Web of Science ®Google Scholar
• Sweeney MP, Bagg J, Baxter WP, et al. Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol 1998;34:123-6
   PubMed Web of Science ®Google Scholar
• Chaushu G, Bercovici M, Dori S, et al. Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer 2000;88:984-7
   PubMed Web of Science ®Google Scholar
• Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J Pain Symptom Manag 2005;30:496-7
   PubMed Web of Science ®Google Scholar
• Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008;30:469-81
   PubMed Web of Science ®Google Scholar
• Popper L, Nolte T, Kaczmarek Z, et al. Intranasal fentanyl for relief of breakthrough pain in patients with cancer. Poster presented at the WCP 2008, Glasgow, Scotland
   Google Scholar
• Kress HG, Orońska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a Phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009;31:1177-91
   PubMed Web of Science ®Google Scholar
• World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Helsinki 1964, amended in Tokyo 1975, Venice 1983, Hong Kong 1989, South Africa 1996 and Edinburgh 2000, clarified in Washington 2002 and Tokyo 2004
   Google Scholar
• Sunshine A, Mulhern SA, Olson N, et al. Comparative sensitivity of stopwatch methodology and conventional pain assessment measures for detecting early response to triptans in migraine: results of a randomized, open-label pilot study. Clin Ther 2006;28:1107-15
   PubMed Web of Science ®Google Scholar
• Desjardins P, Black P, Papageorge M, et al. Ibuprofen arginate provides effective relief from postoperative dental pain with a more rapid onset of action than ibuprofen. Eur J Clin Pharmacol 2002;58:387-94
   PubMed Web of Science ®Google Scholar
• Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94
   PubMed Web of Science ®Google Scholar
• Brown H, Prescott R. Applied Mixed Models in Medicine, 2nd edn. UK: Wiley, 2006.
   Google Scholar
• Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577-84
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995;57:289-300
   Web of Science ®Google Scholar
• Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2
   Web of Science ®Google Scholar
• Dale O, Hjortkjær R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002;46:759-70
   PubMed Web of Science ®Google Scholar
• Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-45
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79:303-12
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;96:1828-33
   PubMed Web of Science ®Google Scholar
• Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
   PubMed Web of Science ®Google Scholar
• Bennett D, Burton AW, Fishman S, et al. Consensus Panel Recommendations for the assessment and management of breakthrough pain. Part 2 Management. P T 2005;30:354-61
   Google Scholar
• Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-16
   Google Scholar
• Nave R, Sides EH, Colberg T, et al. Pharmacokinetics of Intranasal Fentanyl Spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Poster presented at EFIC 2009, Lisbon, Portugal
   Google Scholar
• Nave R, Sides EH, Colberg T, et al. Pharmacokinetics of Intranasal Fentanyl Spray (INFS) in subjects with common cold. Poster presented at EFIC 2009, Lisbon, Portugal
   Google Scholar
• Walker G, Wilcock A, Manderson C, et al. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 2003;17:219-21
   PubMed Web of Science ®Google Scholar